Yearbook of Medical Informatics

LinksSchließen

Referenz

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L. et al.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomized, open-label phase 3 study (KEYNOTE-006).

Lancet 2017;
390 10105 1853-62

Bibliographische Angaben herunterladen

Aufrufen in: